(Q83548592)

English

Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi

scientific article published on 28 February 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

experimental infection

1 reference

based on heuristic

inferred from title

Trypanosoma cruzi

object named as

Trypanosoma cruzi

1 reference

based on heuristic

inferred from title

Mariana R Dominguez

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Jonatan Ersching

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Oscar Bruna-Romero

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Ramon Lemos

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Alexandre V Machado

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Mauricio M Rodrigues

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

José Ronnie C de Vasconcelos

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

28 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

2882-2891

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Immune system recognition of Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

CD8+ T cells in Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Chagasic patients develop a type 1 immune response to Trypanosoma cruzi trans-sialidase

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural CD4+ T-cell responses against Trypanosoma cruzi KMP-11 protein in chronic chagasic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Modulation of CD4(+) T cell-dependent specific cytotoxic CD8(+) T cells differentiation and proliferation by the timing of increase in the pathogen load

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Infection with Trypanosoma cruzi restricts the repertoire of parasite-specific CD8+ T cells leading to immunodominance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Impaired innate immunity in Tlr4(-/-) mice but preserved CD8+ T cell responses against Trypanosoma cruzi in Tlr4-, Tlr2-, Tlr9- or Myd88-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Immunodominance: a new hypothesis to explain parasite escape and host/parasite equilibrium leading to the chronic phase of Chagas' disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Protective Immunity Against Trypanosoma cruzi Infection in a Highly Susceptible Mouse Strain After Vaccination with Genes Encoding the Amastigote Surface Protein-2 and Trans-Sialidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Egress: a receptor-regulated step in lymphocyte trafficking

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Leishmania (Leishmania) amazonensis infection in mice treated with FTY720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.037

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.02.037

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22381075%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83548592&oldid=1799837628"